Streamlining Biosimilars: FDA Takes Steps to Improve Drug Affordability

FDA Action on Biosimilars Signals Progress for Patients and Employers The FDA’s effort to streamline biosimilar development is a welcome step toward improving access to lower-cost medicines while maintaining the rigorous standards that ensure patient safety and efficacy. By reducing…